31602-64-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(5-Tetrazolyl)ethanaMine is used as a building block for the synthesis of pharmaceuticals, due to its versatile reactivity and potential for creating new drug candidates.
Used in Agrochemical Industry:
2-(5-Tetrazolyl)ethanaMine is used as a building block for the synthesis of agrochemicals, due to its versatile reactivity and potential for creating new agrochemical candidates.
Used in Drug Discovery and Development:
2-(5-Tetrazolyl)ethanaMine is used as an important chemical intermediate in drug discovery and development, due to its antimicrobial, anticancer, and anti-inflammatory properties.

Upstream product

• 103392-28-5 2-(1-benzyl-1H-tetrazol-5-yl)-ethylamine 
• 33841-54-2 N-Cbz-1H-tetrazol-5-ethanamine 
• 758697-03-9 (2-trityl-2H-tetrazol-5-yl)-acetonitrile 
• 847830-16-4 [2-(1-benzyl-1H-tetrazol-5-yl)-ethyl]-trityl-amine 
• 114352-61-3 N-[2-(1H-tetrazol-5-yl)-ethyl]-benzamide 

Downstream Products

• 114352-61-3 N-[2-(1H-tetrazol-5-yl)-ethyl]-benzamide 
• 114097-37-9 N-phenyl-N'-[2-(1H-tetrazol-5-yl)-ethyl]-urea 
• 130816-12-5 N-cyanophenyl-N'-2-(5-tetrazolyl)ethyl thiourea 
• 130816-11-4 N-cyanophenyl-N'-2-(5-tetrazolyl)ethyl urea 
• 33841-57-5 2-(1H-tetrazol-5-yl)ethanamine hydrochloride 
• 1421766-15-5 C₂₁H₂₇N₉O₂ 

Relevant academic research and scientific papers

MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF

Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.

New thiadiazole derivatives

The present invention relates to thiadiazole derivatives of formula (I), to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1P1 receptors and thus, they are useful in the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1-phosphate receptors agonists (S1P1), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.

NEW THIADIAZOLE DERIVATIVES

The present invention relates to thiadiazole derivatives of formula (I), to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent agonists of S1P1 receptors and thus, they are useful In the treatment, prevention or suppression of diseases and disorders known to be susceptible to improvement by sphingosine-1-phosphate receptors agonists (S1P1), such as autoimmune diseases, chronic immune and inflammatory diseases, transplant rejection, malignant neoplastic diseases, angiogenic-related disorders, pain, neurological diseases, viral and infectious diseases.

Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)

A known side-activity of the oral potassium-sparing diuretic drug amiloride is inhibition of the enzyme urokinase-type plasminogen activator (uPA, K i = 7 μM), a promising anticancer target. Several studies have demonstrated significant antitum

DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES

Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

VIGABATRIN BIOISOTERES AND RELATED METHODS OF USE

Compounds bioisoteric to vigabatrin and related methods of use.

Carboxylate bioisosteres of pregabalin

Several β-amino tetrazole analogs of gabapentin 1 and pregabalin 2 were prepared by one of two convergent, highly efficient routes, and their affinity for the α2-δ protein examined. Two select compounds with potent affinity for α2-δ,

New substrates and inhibitors of γ-aminobutyric acid aminotransferase containing bioisosteres of the carboxylic acid group: Design, synthesis, and biological activity

A series of potential substrates of γ-aminobutyric acid aminotransferase (GABA-AT) with lipophilic bioisosteres of the carboxylic acid group (2-7) were synthesized and tested. Most of the synthesized compounds showed substrate activities with GABA-AT; 1H-tetrazole-5-propanamine (6) was the best of those tested. The potential time-dependent inhibitor of GABA-AT, 1H-tetrazole-5-(α-vinyl-propanamine) (8), was designed based on the structures of 6 and the antiepilepsy drug vigabatrin (4-aminohex-5-enoic acid, 1). The synthesized compound 8 showed time-dependent inhibition of GABA-AT, but its potency is lower than that of vigabatrin. Methylation of the tetrazole group in 8 resulted in loss of time-dependent activity, suggesting that the tetrazole ring, the carboxylate bioisostere, exists in its deprotonated form in the enzyme active site.

ORGANIC COMPOUNDS

Compounds of Formula (I); in free or salt form, wherein Ra, Rb, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Efficient syntheses of 5-aminoalkyl-1H-tetrazoles and of polyamines incorporating tetrazole rings

(Chemical Equation Presented) Linear Nω-tritylated ω-amino thiobenzylamides and Nα,Nω- ditritylated polyamino mono- or bisthioamides were efficiently converted to the corresponding tetrazole derivatives upon treatment with